Tempest Therapeutics, Inc. Interest Expense
Tempest Therapeutics, Inc. (TPST) reported Interest Expense of $372.00 thousand for the 3-month period ending 2024-06-30, per its 10-Q filed 2024-08-08.
Discontinued › Expense Statement › Interest Expense
us-gaap:InterestExpense · last filed 2024-08-08
- Tempest Therapeutics, Inc. interest expense for the quarter ending 2024-06-30 was $372.00K, a 4.79% increase year-over-year.
- Tempest Therapeutics, Inc. interest expense for the quarter ending 2024-03-31 was $368.00K, a 6.98% increase year-over-year.
- Tempest Therapeutics, Inc. interest expense for the quarter ending 2023-12-31 was $377.00K, a 12.73% decline year-over-year.
- Tempest Therapeutics, Inc. interest expense for the quarter ending 2023-09-30 was $373.00K, a 4.11% decline year-over-year.
- Tempest Therapeutics, Inc. interest expense for fiscal 2023 was $1.45M, a 10.44% decline from fiscal 2022.
- Tempest Therapeutics, Inc. interest expense for fiscal 2022 was $1.62M, a 26.21% increase from fiscal 2021.
- Tempest Therapeutics, Inc. interest expense for fiscal 2021 was $1.28M.
- Tempest Therapeutics, Inc. interest expense for fiscal 2020 was $0.00.
| Period end | Interest Expense 3 month | Interest Expense 6 month | Interest Expense 9 month | Interest Expense 12 month |
|---|---|---|---|---|
| 2024-06-30 | $372.00K 10-Q · filed 2024-08-08 | $740.00K 10-Q · filed 2024-08-08 | $1.12M derived: sum of 3 quarters · filed 2024-08-08 | $1.49M derived: sum of 4 quarters · filed 2024-08-08 |
| 2024-03-31 | $368.00K 10-Q · filed 2024-05-09 | $745.00K derived: sum of 2 quarters · filed 2024-05-09 | $1.12M derived: sum of 3 quarters · filed 2024-05-09 | $1.47M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-12-31 | $377.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $750.00K derived: sum of 2 quarters · filed 2024-03-19 | $1.10M derived: sum of 3 quarters · filed 2024-08-08 | $1.45M 10-K · filed 2024-03-19 |
| 2023-09-30 | $373.00K 10-Q · filed 2023-11-08 | $728.00K derived: sum of 2 quarters · filed 2024-08-08 | $1.07M 10-Q · filed 2023-11-08 | $1.50M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-06-30 | $355.00K 10-Q · filed 2024-08-08 | $699.00K 10-Q · filed 2024-08-08 | $1.13M derived: sum of 3 quarters · filed 2024-08-08 | $1.52M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $344.00K 10-Q · filed 2024-05-09 | $776.00K derived: sum of 2 quarters · filed 2024-05-09 | $1.17M derived: sum of 3 quarters · filed 2024-05-09 | $1.63M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $432.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $821.00K derived: sum of 2 quarters · filed 2024-03-19 | $1.28M derived: sum of 3 quarters · filed 2024-03-19 | $1.62M 10-K · filed 2024-03-19 |
| 2022-09-30 | $389.00K 10-Q · filed 2023-11-08 | $853.00K derived: sum of 2 quarters · filed 2023-11-08 | $1.19M 10-Q · filed 2023-11-08 | $1.52M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $464.00K 10-Q · filed 2023-08-10 | $797.00K 10-Q · filed 2023-08-10 | $1.14M derived: sum of 3 quarters · filed 2023-08-10 | $1.57M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $333.00K 10-Q · filed 2023-05-10 | $671.00K derived: sum of 2 quarters · filed 2023-05-10 | $1.11M derived: sum of 3 quarters · filed 2023-05-10 | $1.38M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $338.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | $775.00K derived: sum of 2 quarters · filed 2023-03-22 | $1.05M derived: sum of 3 quarters · filed 2023-03-22 | $1.28M 10-K · filed 2023-03-22 |
| 2021-09-30 | $437.00K 10-Q · filed 2022-11-08 | $713.00K derived: sum of 2 quarters · filed 2022-11-08 | $944.00K 10-Q · filed 2022-11-08 | $944.00K derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $276.00K 10-Q · filed 2022-08-15 | $507.00K 10-Q · filed 2022-08-15 | $507.00K derived: sum of 3 quarters · filed 2022-08-15 | $507.00K derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | $231.00K 10-Q · filed 2022-05-13 | $231.00K derived: sum of 2 quarters · filed 2022-05-13 | $231.00K derived: sum of 3 quarters · filed 2022-05-13 | $231.00K derived: sum of 4 quarters · filed 2022-05-13 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $0.00 derived: sum of 2 quarters · filed 2022-03-29 | $0.00 derived: sum of 3 quarters · filed 2022-03-29 | $0.00 10-K · filed 2022-03-29 |
| 2020-09-30 | $0.00 10-Q · filed 2021-11-10 | $0.00 derived: sum of 2 quarters · filed 2021-11-10 | $0.00 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $0.00 10-Q · filed 2021-08-12 | $0.00 10-Q · filed 2021-08-12 | ||
| 2018-12-31 | $134.00K 10-K · filed 2019-04-01 | |||
| 2017-12-31 | $288.00K 10-K · filed 2019-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B |